{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:08:57Z","timestamp":1787314137351,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K20720"],"award-info":[{"award-number":["21K20720"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15319"],"award-info":[{"award-number":["22K15319"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20H05798"],"award-info":[{"award-number":["20H05798"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40264-023-01300-9","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T12:02:07Z","timestamp":1682596927000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2033-4246","authenticated-orcid":false,"given":"Takahiro","family":"Niimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Nounin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Unten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Mitsuboshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"1300_CR1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998\u20132006.","journal-title":"JAMA"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7:137\u201355.","journal-title":"Cancer Discov"},{"key":"1300_CR3","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","volume":"27","author":"B Hallberg","year":"2016","unstructured":"Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27:iii4-15.","journal-title":"Ann Oncol"},{"key":"1300_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000219","volume":"2","author":"F Blackhall","year":"2017","unstructured":"Blackhall F, Ross Camidge D, Shaw AT, Soria J-C, Solomon BJ, Mok T, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2: e000219.","journal-title":"ESMO Open."},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","volume":"17","author":"D-W Kim","year":"2016","unstructured":"Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17:452\u201363.","journal-title":"Lancet Oncol"},{"key":"1300_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29\u201339.","journal-title":"Lancet"},{"key":"1300_CR7","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood-2014-12-617779","volume":"126","author":"H Richly","year":"2015","unstructured":"Richly H, Kim TM, Schuler M, Kim D-W, Harrison SJ, Shaw AT, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase\u2013rearranged anaplastic large-cell lymphoma. Blood. 2015;126:1257\u20138.","journal-title":"Blood"},{"key":"1300_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10637-018-0605-x","volume":"36","author":"T Oyakawa","year":"2018","unstructured":"Oyakawa T, Muraoka N, Iida K, Kusuhara M, Kawamura T, Naito T, et al. Crizotinib-induced simultaneous multiple cardiac toxicities. Invest New Drugs. 2018;36:949\u201351.","journal-title":"Invest New Drugs"},{"key":"1300_CR9","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jama.2015.12763","volume":"314","author":"M Imazio","year":"2015","unstructured":"Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015;314:1498\u2013506.","journal-title":"JAMA"},{"key":"1300_CR10","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer. N Engl J Med. 2018;379:2027\u201339.","journal-title":"N Engl J Med"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654\u201367.","journal-title":"Lancet Oncol"},{"key":"1300_CR12","unstructured":"VigiBase. https:\/\/who-umc.org\/vigibase\/. Accessed 10 July 2022."},{"key":"1300_CR13","unstructured":"SQLite. https:\/\/www.sqlite.org\/index.html. Accessed 10 Mar 2022."},{"key":"1300_CR14","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english. Accessed 14 Mar 2022."},{"key":"1300_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1300_CR16","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167\u201377.","journal-title":"N Engl J Med"},{"key":"1300_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917\u201329.","journal-title":"Lancet"},{"key":"1300_CR18","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16:2091\u2013108.","journal-title":"J Thorac Oncol"},{"key":"1300_CR19","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018\u201329.","journal-title":"N Engl J Med"},{"key":"1300_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1300_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2165\/00002018-200730100-00001","volume":"30","author":"M Lindquist","year":"2007","unstructured":"Lindquist M. The need for definitions in pharmacovigilance. Drug Saf. 2007;30:825\u201330.","journal-title":"Drug Saf"},{"key":"1300_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1300_CR23","doi-asserted-by":"publisher","first-page":"57379","DOI":"10.18632\/oncotarget.18283","volume":"8","author":"L Lin","year":"2017","unstructured":"Lin L, Zhao J, Kong N, He Y, Hu J, Huang F, et al. Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. Oncotarget. 2017;8:57379\u201385.","journal-title":"Oncotarget"},{"key":"1300_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1159\/000518081","volume":"14","author":"MP Ulhoi","year":"2021","unstructured":"Ulhoi MP, Sorensen BS, Meldgaard P. Alectinib-induced pleural and pericardial effusions in ALK-positive NSCLC. Case Rep Oncol. 2021;14:1323\u20137.","journal-title":"Case Rep Oncol"},{"key":"1300_CR25","doi-asserted-by":"publisher","first-page":"22137","DOI":"10.18632\/oncotarget.25154","volume":"9","author":"RB Costa","year":"2018","unstructured":"Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, et al. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget. 2018;9:22137\u201346.","journal-title":"Oncotarget"},{"key":"1300_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/1758834015617355","volume":"8","author":"I Sullivan","year":"2016","unstructured":"Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016;8:32\u201347.","journal-title":"Ther Adv Med Oncol."},{"key":"1300_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/med.21476","volume":"38","author":"P Mlad\u011bnka","year":"2018","unstructured":"Mlad\u011bnka P, Applov\u00e1 L, Pato\u010dka J, Costa VM, Remiao F, Pourov\u00e1 J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38:1332\u2013403.","journal-title":"Med Res Rev"},{"key":"1300_CR28","unstructured":"XALKORI PHARMACOLOGY REVIEW, FDA, March 30 (2011), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202570Orig1s000PharmR.pdf. Accessed 21 Sept 2022."},{"key":"1300_CR29","unstructured":"LORBRENA MULTI-DISCIPLINE REVIEW, FDA, December 5 (2017), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210868Orig1s000MultidisciplineR.pdf. Accessed 21 Sept 2022."},{"key":"1300_CR30","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/pharmaceutics13091427","volume":"13","author":"AK Brenner","year":"2021","unstructured":"Brenner AK, Gunnes MW. Therapeutic targeting of the anaplastic lymphoma kinase (ALK) in neuroblastoma-a comprehensive update. Pharmaceutics. 2021;13:1427.","journal-title":"Pharmaceutics"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01300-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:08:38Z","timestamp":1685099318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01300-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01300-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"23 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by grants from the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research [Grant number: 21K20720, 22K15319] and Grant-in-Aid for Transformative Research Areas (B) [Grant number: 20H05798].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from VigiBase, were used under license, and are, therefore, not publicly available. Data are available from VigiBase with the permission of Uppsala Monitoring Centre.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code used when analyzing the data of the current study is available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TN authored the article and performed the statistical analysis. HH conceptualized the study and was involved in planning and interpretation of results. KM, YN, HU, MY, SM, FA, KY, TK, MG, YK, YI, YZ, and KI critically revised the manuscript and interpreted the results. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}